Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

venta libre que apoyen los esfuerzos de la personas para llevar vidas satisfactorias y gratificantes. Para obtener más información sobre Taiho Pharmaceutical, por favor visite http://www.taiho.co.jp/english/ . Con sede en Tokio, el presidente de la compañía es Masayuki Kobayashi .

Acerca de Otsuka Holdings Co., Ltd.
El grupo Otsuka es una organización global de 156 compañías sanitarias con casi 40.000 empleados. Otsuka Holdings Co., Ltd., es la compañía holding del Grupo. Las principales compañías operativas son Otsuka Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Factory, Inc.; Taiho Pharmaceutical Co., Ltd.; Otsuka Warehouse Co., Ltd.; y Otsuka Chemical Co., Ltd. El Grupo opera en 25 países y regiones, realizando negocios diversificados en cuatro segmentos, todos ellos conectados por un enfoque en la salud: farmacéuticos, nutracéuticos, productos de consumo y otras áreas de producto. La filosofía corporativa del Grupo de "el personal de Otsuka crea nuevos productos para una mejor salud en todo el mundo" está respaldada por la ética corporativa de "JISSHO (prueba mediante ejecución) y SOZOSEI (creatividad)". El grupo Otsuka busca impulsar una cultura y vitalidad propias de una empresa implicada con la salud humana y crear productos innovadores que contribuyan al bienestar y salud de las personas en todo el mundo. Para más información, visite el sitio web de la compañía en http://www.otsuka.com/en/.

Contacto:
Mitsutoshi Utatsu
Public Relations Dept.
Taiho Pharmaceutical Co., Ltd.
Tel: +81-3-3293-2878
e-mail: th-102a@taiho.co.jp
* Para consultas, contáctenos por e-mail. 

'/>"/>
SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
(Date:7/28/2014)... ResMed (NYSE: RMD ), innovatore e pioniere ... respiratori del sonno (SDB) e altre patologie croniche del ... il produttore Taiwanese di dispositivi medicali, APEX Medical Corp. ... in testa, che violano i brevetti, utilizzate con l,APEX ... Corte Regionale Distrettuale di Monaco , ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
(Date:7/28/2014)... The report, “Blowing Agents Market by ... and Forecasts to 2019” defines and segments the ... of the global consumption volume and value. , ... 39 figures spread through 226 Pages and in-depth ... , Blowing agents are highly utilized materials as ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... -- Researchers from The University of Texas Health Science Center ... have identified a combination of pills that cures 9 of ... sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent ... patients, according to the study published today in The ... U.S. , Eric Lawitz, M.D., clinical professor in the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The North America ... & antioxidants market in North America with analysis and forecast ... $539.9 million in 2012 to $812.7 million by 2018, at ... through the TOC of the North America Carotenoids & Antioxidants ... provided. It also provides a glimpse of the segmentation in ...
Breaking Medicine News(10 mins):Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... of Pharmaceutical Marketing Industry Due to New PhRMA ... 6 Pharmaceutical marketers are taking on the ... Systems, a unique marketing company whose integrated engagement ... the sector. In the past two years the ...
... A survey recently conducted by the Society of ... Compliance Association (HCCA) reveals that the declining economy may ... in business. In addition, this increased risk is ... risks are expected to at best hold steady, if ...
... /PRNewswire/ -- Akerman Senterfitt, one of the ... top 100 firms in the U.S., today announced that ... the auspices of the American Health Lawyers Association (AHLA) ... and issues concerning privilege and confidentiality. The live audiocast ...
... POINT, N.Y., Jan. 6 Akrimax Pharmaceuticals, LLC ... of pharmaceutical products for a global company beginning ... partners in a competitive process.Akrimax President Alan L. ... to acquire the Rouses Point facility which possesses ...
... KENILWORTH, N.J., Jan. 6 Schering-Plough Corporation (NYSE: ... results for the 2008 fourth quarter and full year on ... that day, Schering-Plough will conduct a conference call to review ... Fred Hassan, Schering-Plough,s chairman and CEO, and other members of ...
... for expanding role of patient flow automation PITTSBURGH, Jan. ... its clients, now more than 700 hospitals, solve their ... to increase capacity and improve patient flow is now ... have postponed building and expansion plans because of the ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 3Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Akrimax Pharmaceuticals Announces Manufacturing Partnership 2Health News:Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... be more comfortable, and you will too., ... secure and to avoid the knotty problems ... twill ties, consider the Dale® Tracheostomy Tube ... the narrow fastener tabs of the Dale® ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: